ArticleDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2010
[The IOL-Vip system : Principles and clinical application].
Article in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Summary of the Therapeutic Options for Patients with Dry and Neovascular AMD.Journal of clinical medicine · 2024Review
- Current Modalities for Low Vision Rehabilitation.Cureus · 2021Review
- High-addition segmented refractive bifocal intraocular lens in inactive age-related macular degeneration: A multicenter pilot study.PloS one · 2021Article
- Current Approaches to Low Vision (Re)HabilitationTurkish journal of ophthalmology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are various retinal disorders that cause macular degeneration. However, age-related macular degeneration (ARMD) is the main cause of legal blindness in developed countries. Even today the end stage of this disease can often not be avoided. Patients suffer from central scotoma and severe vision loss. Low vision aids may help in certain situations, but these devices are often functionally and cosmetically inadequate. The implantation of the IOL-Vip system is a new surgical alternative. The lens system consists of a high negative power lens (-64 D) which is implanted in the capsular bag and a high positive power lens (+53 D) which is implanted in the anterior chamber. An intraocular Galilean telescope is reproduced by this arrangement. The IOL-Vip system provides a magnification of 1.3 without notably compromising the peripheral visual field. Investigations have shown that visual improvement can be achieved after implantation of the IOL-Vip system combined with a rehabilitation program. In particular orientation and the ability of patients to perform everyday tasks showed improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.